Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Aims: To investigate the characteristics of spinal adverse events after non-operative treatment for spinal metastases with intermediate instability and to discuss clinical considerations when selecting non-operative treatment.

Methods: This study included 56 patients with spinal metastases who had Spinal Instability Neoplastic Scores (SINS) of 7-12 and who underwent radiotherapy and intensive rehabilitation without a bed rest period as initial treatment between 2020 and 2023. We evaluated progression of paralysis and changes in spinal alignment before treatment, within 1 month, 1 to 6 months, and more than 6 months after treatment.

Results: Paralysis progressed within 1 month after treatment in 7 of 56 patients (12.5%). Pre-treatment paralysis and SINS ≥ 11 were significantly associated with progression of paralysis. Alignment changes occurred in 18 of 56 patients (32.1%), with a similar incidence in patients with SINS ≥ 11 and ≤ 10. Fifteen of 44 patients (34.1%) without pre-treatment paralysis had alignment changes, but 1 patient (2.3%) experienced progression of paralysis due to increased instability within 1 month. All 3 patients whose paralysis progressed despite no evidence of malignant spinal cord compression before or after treatment had SINS ≥ 11 and showed vertebral height reduction and kyphosis progression within 1 month.

Conclusion: Patients with pre-treatment paralysis and SINS ≥ 11 can progress to paralysis early; therefore, careful observation and imaging examinations are recommended early after treatment. If spinal alignment worsens, the treatment plan should be reconsidered, including restrictions of activity and surgical treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00586-025-08817-wDOI Listing

Publication Analysis

Top Keywords

treatment spinal
12
spinal metastases
12
progression paralysis
12
pre-treatment paralysis
12
treatment
9
paralysis
9
clinical considerations
8
non-operative treatment
8
spinal
8
metastases intermediate
8

Similar Publications

Spinal muscular atrophy (SMA) is a neuromuscular disease caused by low levels of SMN protein. Several therapeutic approaches boosting SMN are approved for human patients, delivering remarkable improvements in lifespan and symptoms. However, emerging phenotypes, including neurodevelopmental comorbidities, are being reported in some treated SMA patients, indicative of alterations in brain development.

View Article and Find Full Text PDF

Purpose: To investigate the images and treatment differences for Type IIIa atlantoaxial rotary dislocation (AARD) by comparing the imaging characteristics of patients with Type III and Type IIIa AARD.

Methods: The present study retrospectively analyzed a cohort of 35 patients who underwent posterior C1-C2 intra-articular fusion due to AARD from our hospital database. Among them, 23 patients were diagnosed with Type III AARD, while the remaining 12 patients were diagnosed with Type IIIa AARD.

View Article and Find Full Text PDF

The authors present treatment of patients with spinal injury complicated by extensive multiple pressure sores. A comprehensive preoperative management was followed by staged surgical treatment. Advisability of deep bedsore closure with full-layer flaps and staged interventions was justified.

View Article and Find Full Text PDF

Dual Role of DLK1 in GnRH Neuron Ontogeny.

Stem Cell Rev Rep

September 2025

Stem Cells and Metabolism Research Program (STEMM), Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, 00014, Finland.

Mutations in Delta Like Non-Canonical Notch Ligand 1 (DLK1), a paternally expressed imprinted gene, underlie central precocious puberty (CPP), yet the mechanism remains unclear. To test the hypothesis that DLK1 plays a role in gonadotropin releasing hormone (GnRH) neuron ontogeny, 75 base pairs were deleted in both alleles of DLK1 exon 3 with CRISPR-Cas9 in human pluripotent stem cells (hPSCs). This line, exhibiting More than 80% loss of DLK1 protein, was differentiated into GnRH neurons by dual SMAD inhibition (dSMADi), FGF8 treatment and Notch inhibition, as previously described, however, it did not exhibit accelerated GNRH1 expression.

View Article and Find Full Text PDF

Peripheral sensory neurons regenerate their axons after injury to regain function, but this ability declines with age. The mechanisms behind this decline are not fully understood. While excessive production of endothelin 1 (ET-1), a potent vasoconstrictor, is linked to many diseases that increase with age, the role of ET-1 and its receptors in axon regeneration is unknown.

View Article and Find Full Text PDF